CASSAVA SCIENCES INC
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
SAVA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US69562K5065 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 6801 N CAPITAL OF TEXAS HIGHWAY, 78731 AUSTIN
- Website:
- https://www.cassavasciences.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for Central Nervous System (CNS) disorders. The company's lead drug candidate is simufilam, a proprietary, investigational oral small molecule designed to modulate the activity of the filamin A (FLNA) protein, a key regulator in neuronal development. Cassava's primary development program is advancing simufilam as a potential therapy for tuberous sclerosis complex (TSC)-related epilepsy, supported by preclinical data showing a reduction in seizure activity. The company is also exploring the potential application of simufilam for other CNS indications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CASSAVA SCIENCES INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CASSAVA SCIENCES INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CASSAVA SCIENCES INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
